Production (Stage)
Haemonetics Corporation
HAE
$67.53
$1.472.23%
NYSE
| 03/29/2025 | 12/28/2024 | 09/28/2024 | 06/29/2024 | 03/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 167.68M | 130.07M | 123.81M | 114.89M | 117.56M |
| Total Depreciation and Amortization | 108.89M | 106.42M | 100.92M | 94.86M | 88.62M |
| Total Amortization of Deferred Charges | 6.70M | 8.60M | 8.60M | 8.60M | 8.60M |
| Total Other Non-Cash Items | 422.00K | 14.53M | 18.50M | 22.47M | 41.68M |
| Change in Net Operating Assets | -101.96M | -130.36M | -166.89M | -105.58M | -74.70M |
| Cash from Operations | 181.73M | 129.25M | 84.94M | 135.24M | 181.75M |
| Capital Expenditure | -39.28M | -30.32M | -25.65M | -38.33M | -38.13M |
| Sale of Property, Plant, and Equipment | 23.25M | 21.35M | 21.44M | 21.77M | 1.81M |
| Cash Acquisitions | -150.91M | -150.91M | -394.76M | -393.00M | -243.85M |
| Divestitures | 43.29M | 1.50M | 1.50M | 1.50M | 1.50M |
| Other Investing Activities | -38.26M | -34.62M | -47.09M | -38.26M | -43.72M |
| Cash from Investing | -161.90M | -192.99M | -444.56M | -446.33M | -322.39M |
| Total Debt Issued | 950.00M | 950.00M | 1.06B | 1.06B | 110.00M |
| Total Debt Repaid | -502.69M | -564.63M | -566.56M | -658.26M | -72.25M |
| Issuance of Common Stock | 8.33M | 8.30M | 7.68M | 8.12M | 7.21M |
| Repurchase of Common Stock | -235.24M | -85.24M | -84.84M | -14.15M | -5.89M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -111.58M | -111.67M | -111.46M | -23.26M | -922.00K |
| Cash from Financing | 108.82M | 196.77M | 304.82M | 372.45M | 38.16M |
| Foreign Exchange rate Adjustments | -685.00K | -6.16M | 3.08M | -2.66M | -3.19M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 127.96M | 126.87M | -51.72M | 58.71M | -105.67M |